X. Li, E. Pequignot, D. Panebianco
Feb 1, 2005
Citations
0
Influential Citations
3
Citations
Quality indicators
Journal
Clinical Pharmacology & Therapeutics
Abstract
Aprepitant (APR) is the first neurokinin‐1 (NK1) receptor antagonist approved for use with a corticosteroid and a 5‐hydroxytryptamine3 (5HT3) receptor antagonist in the prevention of chemotherapy induced nausea and vomiting (CINV). Dolasetron (DOL) is a 5HT3 antagonist that is converted to the active metabolite hydrodolasetron (HDOL). Metabolism via CYP2D6 contributes significantly to the elimination of HDOL. Because APR may be coadministered with different 5HT3 antagonists including DOL, the purpose of this study was to determine if APR alters the pharmacokinetic profile of HDOL in CYP2D6 extensive metabolizers (EM) and poor metabolizers (PM). This was an open‐label, 2‐period, crossover study in which twelve healthy subjects (N=6 EM's and N=6 PM's) received 2 treatments. Treatment A consisted of a single oral dose of 100‐mg DOL. In treatment B, subjects received simultaneously 100‐mg oral DOL and 125‐mg oral APR at 0 hours, followed by single oral doses of 80‐mg APR 24 hours and 48 hours later. The pharmacokinetic data of HDOL are shown in the table below. The data suggest that APR does not affect the pharmacokinetics of HDOL in CYP2D6 extensive or poor metabolizers.